

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee : 216

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣750佰萬元(NTD 750mn)

營業項目Business：

原料藥API (55.59%)

中間體Intermediate (38.43%)

特用化學品 Custom-made chemicals (5.98%)

公司概況 Outline

	Y2014	Y2015
歐洲 Europe	42.65%	36.13%
美洲 America	21.70%	32.09%
亞洲 Asia	18.18%	19.60%
國內 Taiwan	16.63%	9.22%
其他 others	0.84%	2.96%
合計 Total	100.00%	100.00%

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:

生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:

製劑中之有效成分 Treatable ingredient



下游

Downstream

製劑: 成品藥 Formulation

旭富營業範圍
SCI's businesses

營運概況-IS

Unit: K NTD

	2015 Q1	2015 Q2	2015 Q3	2015.Oct
營收Sales	443,065	579,644	438,507	198,030
營業成本COGS	(273,443)	(360,661)	(292,627)	(119,539)
毛利Gross Profit	169,622	218,983	145,880	78,491
毛利率 GP Ratio	38.3%	37.8%	33.3%	39.6%
營業費用Operating Expense	(53,885)	(64,179)	(50,272)	(24,361)
營業利益Operating Income	115,737	154,804	95,608	54,130
營業外損益Non-Operating	(2,070)	(5,449)	19,441	(3,157)
稅前淨利 Net Profit before Tax	113,667	149,355	115,049	50,973
所得稅Income Tax	(20,849)	(24,605)	(19,847)	
本期淨利Net Profit after Tax	92,818	124,750	95,202	

產品組合-Products

Y2012	%		Y2013	%		Y2014	%
V.A.	18.66%		PGA	18.31%		PGA	17.49%
PGA	16.61%		Di-VaNa	16.92%		Di-VANa	10.09%
Di-VaNa	15.97%		S20/38	8.39%		LPF.Na	8.74%
PPON	7.88%		V.A.	8.23%		S20/38	8.25%
Pent-2	4.78%		LPF.Na	6.58%		V.A.	8.15%
5-HMT	4.33%		PPON	6.53%		DBS	4.60%
M85	3.89%		5-HMT	4.51%		5-HMT	4.12%
DBS	2.73%		PEB.Na	3.98%		NaVA	3.65%
M115	2.59%		NaVa	3.34%		Pent-2	3.64%
M74	2.18%		DBS	2.63%		T115	3.33%
Total	79.62%		Total	79.42%		Total	72.06%

No.	Product	%	2015 Sales (NT\$)
1	HOCLQ Sulfate	22.15%	367,526,433
2	PGA	16.02%	265,876,797
3	V.A.	11.43%	189,656,214
4	LPF.Na	8.14%	135,143,000
5	Di-VaNa	5.74%	95,202,846
6	S2038	4.36%	72,402,057
7	DBS	3.26%	54,030,549
8	5-HMT	2.82%	46,770,544
9	Pent-2	2.50%	41,520,945
10	NaVA	2.10%	34,866,423


產品介紹Product

Hydroxychloroquine sulfate

- ✓ 風濕性關節炎藥物 For rheumatoid arthritis
- ✓ 8個客戶 8 customers
- ✓ 2015sales: 367M

產品介紹Product

● Pyrogallolaldehyde (PGA) - Benserazide



✓ 治療帕金森氏症之中間體

Intermediate for Parkinson's Disease


✓ 2個客戶

2 customer

✓ 2015 sales: 266M


產品介紹Product

Anti-inflammatory (Loxoprofen sodium)



日本市場200-300公噸
Japan market: 200-300MT
2015 sales: 135M

S20/38



臨床藥物
Medication in clinical trial
2015 sales: 72M

產品介紹Product

Valproic Acid (VA)




✓ 20個客戶

20 customers

✓ 2015 sales: 190M

產品介紹Product

● Divalproex Sodium (Di-Va)




- ✓ 學名藥於2009推出
- ✓ 12個客戶
- ✓ 2015 sales: 95M

Generic came out in 2009
12 customers


產品介紹Product

Pentobarbital Sodium (鎮定安眠用, calmative)



2015 sales:29M

Pent-2



2015 sales:41M

產品介紹Product

Antidepressant (Duloxetine)


- ✓ 2013年底專利到期 Patent expired in the end of 2013
- ✓ 2014 sales: 12 M
- ✓ 2015 sales: 32M

Antidepressant (S-MMAA)

- ✓ Duloxetine之中間體 intermediate of Duloxetine
- ✓ 2014 sales: 27 M
- ✓ 2015 sales: 22 M


產品介紹Product

Sodium Valproate (NaVA)



- ✓ 24 客戶 24 customers
- ✓ 2015 sales: 35M

5-HMT – Ritonavir, Lopinavir



- ✓ 愛滋病藥物中間體
For AIDS treatment
- ✓ 2015 sales: 47M

GMP Status(GMP現況)

<i>API</i>	<i>CGMP Certified (TFDA)</i>	<i>CEP (EDQM)</i>	<i>DMF (USA)</i>	<i>MF (Japan)</i>	<i>DMF (Canada)</i>
Valproic Acid (*) (#)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011		
Sodium Valproate	2004	2006			
Divalproex Sodium (**)(#)	2005		2005		2010
Bisoprolol Fumarate	2006				
Pentobarbital Sodium	2009	2011			
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011	2014			
Duloxetine Hydrochloride	2012	2014	2010/2011		
Thiopental	2012				
Loxoprofen Sodium Hydrate	2012			2011	
Articaine Hydrochloride	2013	2014	2014		
Hydroxychloroquine Sulfate(#)	2014		2014		2014
Clindamycin Palmitate HCl			2011		
Cyclophosphamide	2014		2012		
Brinzolamide	2015		2015		
Probucol	2015		2004		

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010, (#) FDA inspection: Dec. 2014.

簡報完畢



敬請指教